Trade-Ideas LLC identified Inovio Pharmaceuticals Inc (NYSEMKT:INO) as a “barbarian at the gate” (strong stocks crossing above resistance with today’s range greater than 200%) candidate. Inovio Pharmaceuticals, Inc. (NYSEMKT:INO), together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 3 analysts that rate Inovio Pharmaceuticals Inc (NYSEMKT:INO) a buy, no analysts rate it a sell, and none rate it a hold. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was 12.69% in last session and finished the day at $3.64. Traded volume was 17.44million shares in the last session and the average volume of the stock remained 7.60million shares. The beta of the stock remained 3.55. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 0.30%.
HealthBank is run by Northwest Biotherapeutics Inc (NASDAQ:NWBO), a publicly traded cancer immunotherapy company based in Bethesda, Md. It charges $2,000 for processing and a year of storage, plus $195 for each subsequent year (about $16 a month). Northwest Biotherapeutics, Inc (NASDAQ:NWBO) rose 15.09 percent to $7.78 Thursday on volume of 3.19million shares. The intra-day range of the stock was $6.90 to $8.09. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has a market capitalization of $337.68million.
Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) were the target of a significant growth in short interest in the month of January. As of March 14th, there was short interest totaling 15,610,186 shares, a growth of 51.8% from the February 28th total of 10,280,960 shares, Stock Ratings News reports. Peregrine Pharmaceuticals (NASDAQ:PPHM)’s stock on Mar 27, 2014 reported a increase of 5.41% to the closing price of $1.95. Its fifty two weeks range is $1.11 -$3.18. The total market capitalization recorded $344.14million. The overall volume in the last trading session was 3.07million shares. In its share capital, PPHM has 163.22million outstanding shares.
Trade-Ideas LLC identified Dyax Corporation (NASDAQ:DYAX) as a “dead cat bounce” (down big yesterday but up big today) candidate. Dyax Corp. (NASDAQ:DYAX), a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. On Thursday, shares of Dyax Corp. (NASDAQ:DYAX) advanced 5.19% to close the day at $8.71. Company return on investment (ROI) is -15.80% and its monthly performance is recorded as -19.50%. Dyax Corp. (NASDAQ:DYAX) quarterly revenue growth is 13.41%.